News

Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Novo exits Hims & Hers partnership, citing ‘deceptive marketing’ concerns
Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...
Hims & Hers: Panic Sell Or Opportunistic Buy?
The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Forbes1d
HIMS Stock To $25?
Hims & Hers Health (NASDAQ: HIMS) experienced a devastating 35% stock crash on June 23, 2025, after Novo Nordisk abruptly terminated their brief partnership. The dramatic sell-off reflects not ...
Stocktwits on MSN12h
Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk Breakup
Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their ...
Zacks.com on MSN22h
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has increasingly prioritized weight loss as a key area of growth and innovation in its healthcare platform. In recent months, ...
Hims & Hers core revenue growth has ‘slowed sharply,’ says BofA
BofA analyst Allen Lutz estimates Hims & Hers’ year-over-year core revenue growth has “slowed sharply,” from about 45% in Q3 of 2024 to 29% in Q1 of 2025, despite a tailwind from shifting customers to ...